This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mishina, Y. Articles by Behringer, R. R. Search for Related Content PubMed PubMed Citation Articles by Mishina, Y. Articles by Behringer, R. R.

High Specificity of Müllerian-Inhibiting Substance Signaling in Vivo¹

Department of Molecular Genetics (Y.M., D.J.W., R.R.B.), The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030; Unité de Recherches sur l’Endocrinologie du Développement (C.R.), INSERM U. 493, École Normale Supérieure, Département de Biologie, 92120 Montrouge, France

Address all correspondence and requests for reprints to: Department of Molecular Genetics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030. E-mail: bhr{at}molgen.mda.uth.tmc.edu

Female transgenic mice that ectopically express high levels of human Müllerian-inhibiting substance (hMIS) under the control of the mouse metallothionein (MT) promoter lack a uterus, oviducts, and ovaries. The loss of the uterus and oviducts is consistent with the known activities for MIS. However, it is not clear if the loss of the ovaries in these transgenic females is caused by interactions of MIS with its normal receptor signaling pathway or by abnormal interactions with other transforming growth factor-ß (TGF-ß) super family receptor signaling pathways. To address this question, female mice carrying the MT-hMIS transgene that were also homozygous for a targeted deletion of the MIS type II receptor gene were generated. Although these females had high levels of circulating hMIS, they had normal reproductive tracts and ovaries with germ cells. In addition, these females were able to become pregnant and gave birth to pups. These findings demonstrate that all of the abnormalities of the reproductive system that are found in female transgenic mice that ectopically express high levels of hMIS are caused by signaling through the MIS type II receptor. These in vivo data demonstrate a high specificity for MIS and its receptor. 140: 2084–2088, 1999)

This article has been cited by other articles:

				G.D. Orvis, S.P. Jamin, K.M. Kwan, Y. Mishina, V.M. Kaartinen, S. Huang, A.B. Roberts, L. Umans, D. Huylebroeck, A. Zwijsen, et al. Functional Redundancy of TGF-beta Family Type I Receptors and Receptor-Smads in Mediating Anti-Mullerian Hormone-Induced Mullerian Duct Regression in the Mouse Biol Reprod, June 1, 2008; 78(6): 994 - 1001. [Abstract] [Full Text] [PDF]

				G. C. Rodriguez, B.J. Rimel, W. Watkin, J. M. Turbov, C. Barry, H. Du, G. L. Maxwell, and J.M. Cline Progestin Treatment Induces Apoptosis and Modulates Transforming Growth Factor-{beta} in the Uterine Endometrium Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 578 - 584. [Abstract] [Full Text] [PDF]

				E. Nilsson, N. Rogers, and M. K Skinner Actions of anti-Mullerian hormone on the ovarian transcriptome to inhibit primordial to primary follicle transition Reproduction, August 1, 2007; 134(2): 209 - 221. [Abstract] [Full Text] [PDF]

				C. Morinaga, D. Saito, S. Nakamura, T. Sasaki, S. Asakawa, N. Shimizu, H. Mitani, M. Furutani-Seiki, M. Tanaka, and H. Kondoh The hotei mutation of medaka in the anti-Mullerian hormone receptor causes the dysregulation of germ cell and sexual development PNAS, June 5, 2007; 104(23): 9691 - 9696. [Abstract] [Full Text] [PDF]

				N. Josso, C. Belville, N. di Clemente, and J.-Y. Picard AMH and AMH receptor defects in persistent Mullerian duct syndrome Hum. Reprod. Update, July 1, 2005; 11(4): 351 - 356. [Abstract] [Full Text] [PDF]

				H. Chang, C. W. Brown, and M. M. Matzuk Genetic Analysis of the Mammalian Transforming Growth Factor-{beta} Superfamily Endocr. Rev., December 1, 2002; 23(6): 787 - 823. [Abstract] [Full Text] [PDF]

				R. Varghese, A. D. Gagliardi, P. E. Bialek, S.-P. Yee, G. F. Wagner, and G. E. Dimattia Overexpression of Human Stanniocalcin Affects Growth and Reproduction in Transgenic Mice Endocrinology, March 1, 2002; 143(3): 868 - 876. [Abstract] [Full Text] [PDF]

				G. C. Rodriguez, N. P. Nagarsheth, K. L. Lee, R. C. Bentley, D. K. Walmer, M. Cline, R. S. Whitaker, P. Isner, A. Berchuck, R. K. Dodge, et al. Progestin-Induced Apoptosis in the Macaque Ovarian Epithelium: Differential Regulation of Transforming Growth Factor-{beta} J Natl Cancer Inst, January 2, 2002; 94(1): 50 - 60. [Abstract] [Full Text] [PDF]

				Y. Ikeda, A. Nagai, M.-a. Ikeda, and S. Hayashi Increased Expression of Mullerian-Inhibiting Substance Correlates with Inhibition of Follicular Growth in the Developing Ovary of Rats Treated with E2 Benzoate Endocrinology, January 1, 2002; 143(1): 304 - 312. [Abstract] [Full Text] [PDF]

				J. Teixeira, S. Maheswaran, and P. K. Donahoe Mullerian Inhibiting Substance: An Instructive Developmental Hormone with Diagnostic and Possible Therapeutic Applications Endocr. Rev., October 1, 2001; 22(5): 657 - 674. [Abstract] [Full Text] [PDF]

				S. Nef and L. F. Parada Hormones in male sexual development Genes & Dev., December 15, 2000; 14(24): 3075 - 3086. [Full Text]

				H. Chong, S. A. Pangas, D. J. Bernard, E. Wang, J. Gitch, W. Chen, L. B. Draper, E. T. Cox, and T. K. Woodruff Structure and Expression of a Membrane Component of the Inhibin Receptor System Endocrinology, July 1, 2000; 141(7): 2600 - 2607. [Abstract] [Full Text] [PDF]

				A. L. L. Durlinger, P. Kramer, B. Karels, F. H. de Jong, J. Th. J. Uilenbroek, J. A. Grootegoed, and A. P. N. Themmen Control of Primordial Follicle Recruitment by Anti-Mullerian Hormone in the Mouse Ovary Endocrinology, December 1, 1999; 140(12): 5789 - 5796. [Abstract] [Full Text]